Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) and eXoZymes (NASDAQ:EXOZ – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.
Volatility and Risk
Iovance Biotherapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, eXoZymes has a beta of 3.14, indicating that its share price is 214% more volatile than the S&P 500.
Profitability
This table compares Iovance Biotherapeutics and eXoZymes’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Iovance Biotherapeutics | -89.11% | -40.51% | -31.65% |
| eXoZymes | N/A | -292.15% | -158.66% |
Institutional and Insider Ownership
Earnings and Valuation
This table compares Iovance Biotherapeutics and eXoZymes”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Iovance Biotherapeutics | $263.50 million | 14.78 | -$390.98 million | ($0.73) | -11.78 |
| eXoZymes | $70,000.00 | 874.97 | -$9.16 million | ($1.19) | -5.55 |
eXoZymes has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Iovance Biotherapeutics and eXoZymes, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Iovance Biotherapeutics | 2 | 2 | 7 | 0 | 2.45 |
| eXoZymes | 1 | 0 | 0 | 0 | 1.00 |
Iovance Biotherapeutics presently has a consensus price target of $8.89, suggesting a potential upside of 3.36%. Given Iovance Biotherapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than eXoZymes.
Summary
Iovance Biotherapeutics beats eXoZymes on 8 of the 14 factors compared between the two stocks.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
About eXoZymes
eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
